• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二氟甲基-1,3,4-噁二唑类化合物是组蛋白去乙酰化酶的选择性、基于机制且本质不可逆的抑制剂。

Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase .

机构信息

Department of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, Bonn 53121, Germany.

Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.

出版信息

J Med Chem. 2023 Oct 12;66(19):13821-13837. doi: 10.1021/acs.jmedchem.3c01345. Epub 2023 Oct 2.

DOI:10.1021/acs.jmedchem.3c01345
PMID:37782298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10591924/
Abstract

Histone deacetylase (HDAC6) is an important drug target in oncological and non-oncological diseases. Most available HDAC6 inhibitors (HDAC6i) utilize hydroxamic acids as a zinc-binding group, which limits therapeutic opportunities due to its genotoxic potential. Recently, difluoromethyl-1,3,4-oxadiazoles (DFMOs) were reported as potent and selective HDAC6i but their mode of inhibition remained enigmatic. Herein, we report that DFMOs act as mechanism-based and essentially irreversible HDAC6i. Biochemical data confirm that DFMO is a tight-binding HDAC6i capable of inhibiting HDAC6 via a two-step slow-binding mechanism. Crystallographic and mechanistic experiments suggest that the attack of by the zinc-bound water at the sp carbon closest to the difluoromethyl moiety followed by a subsequent ring opening of the oxadiazole yields deprotonated difluoroacetylhydrazide as active species. The strong anionic zinc coordination of and the binding of the difluoromethyl moiety in the P571 pocket finally result in an essentially irreversible inhibition of HDAC6.

摘要

组蛋白去乙酰化酶(HDAC6)是肿瘤和非肿瘤疾病中一个重要的药物靶点。大多数现有的 HDAC6 抑制剂(HDAC6i)都利用羟肟酸作为锌结合基团,但其遗传毒性潜力限制了其治疗机会。最近,二氟甲基-1,3,4-噁二唑(DFMOs)被报道为有效的、选择性的 HDAC6i,但它们的抑制机制仍然很神秘。在这里,我们报告说,DFMOs 是一种基于机制的、基本上不可逆的 HDAC6i。生化数据证实,DFMO 是一种紧密结合的 HDAC6i,能够通过两步慢结合机制抑制 HDAC6。晶体学和机制实验表明,锌结合水攻击离二氟甲基基团最近的 sp 碳原子,随后噁二唑环打开,生成带负电荷的二氟乙酰基酰肼 作为活性物质。DFMO 中强烈的阴离子锌配位和二氟甲基部分在 P571 口袋中的结合最终导致 HDAC6 的基本不可逆抑制。

相似文献

1
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase .二氟甲基-1,3,4-噁二唑类化合物是组蛋白去乙酰化酶的选择性、基于机制且本质不可逆的抑制剂。
J Med Chem. 2023 Oct 12;66(19):13821-13837. doi: 10.1021/acs.jmedchem.3c01345. Epub 2023 Oct 2.
2
Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.二氟甲基-1,3,4-噁二唑类 HDAC6 抑制剂的作用机制和结构见解。
Int J Mol Sci. 2024 May 28;25(11):5885. doi: 10.3390/ijms25115885.
3
Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.二氟甲基-1,3,4-噁二唑类化合物是组蛋白去乙酰化酶 6 的缓慢结合底物类似物抑制剂,具有前所未有的同型选择性。
J Biol Chem. 2023 Jan;299(1):102800. doi: 10.1016/j.jbc.2022.102800. Epub 2022 Dec 15.
4
Development of the first non-hydroxamate selective HDAC6 degraders.开发首个非羟肟酸类选择性 HDAC6 降解剂。
Chem Commun (Camb). 2022 Oct 4;58(79):11087-11090. doi: 10.1039/d2cc03712b.
5
2-(Difluoromethyl)-1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?2-(二氟甲基)-1,3,4-恶二唑:选择性组蛋白去乙酰化酶6调节的未来?
ACS Pharmacol Transl Sci. 2024 Feb 20;7(3):899-903. doi: 10.1021/acsptsci.4c00031. eCollection 2024 Mar 8.
6
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.选择性和生物可利用的 HDAC6 2-(二氟甲基)-1,3,4-噁二唑底物抑制剂及其生物活化机制的建模。
J Med Chem. 2023 Oct 26;66(20):14188-14207. doi: 10.1021/acs.jmedchem.3c01269. Epub 2023 Oct 5.
7
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.羟肟酸和二氟甲基恶二唑类组蛋白去乙酰化酶 6 抑制剂的体外和细胞选择性。
Int J Mol Sci. 2023 Mar 1;24(5):4720. doi: 10.3390/ijms24054720.
8
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6).通过组蛋白去乙酰化酶 6(HDAC6)对恶二唑类抑制剂的水解进行全面的机制研究。
ACS Chem Biol. 2023 Jul 21;18(7):1594-1610. doi: 10.1021/acschembio.3c00212. Epub 2023 Jul 1.
9
Recent advances in the discovery of potent and selective HDAC6 inhibitors.强效和选择性HDAC6抑制剂发现方面的最新进展。
Eur J Med Chem. 2018 Jan 1;143:1406-1418. doi: 10.1016/j.ejmech.2017.10.040. Epub 2017 Oct 16.
10
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.HDAC6 选择性羟肟酸抑制剂的不寻常锌结合模式。
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13459-13464. doi: 10.1073/pnas.1718823114. Epub 2017 Dec 4.

引用本文的文献

1
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential.基于酰肼的组蛋白去乙酰化酶抑制剂的研究进展:近期发展与治疗潜力综述
J Med Chem. 2025 Jul 24;68(14):14171-14194. doi: 10.1021/acs.jmedchem.5c01677. Epub 2025 Jul 10.
2
DCAF16-Based Covalent Molecular Glues for Targeted Protein Degradation of Histone Deacetylases.用于靶向降解组蛋白去乙酰化酶的基于DCAF16的共价分子胶
Arch Pharm (Weinheim). 2025 Jul;358(7):e70045. doi: 10.1002/ardp.70045.
3
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.

本文引用的文献

1
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6).通过组蛋白去乙酰化酶 6(HDAC6)对恶二唑类抑制剂的水解进行全面的机制研究。
ACS Chem Biol. 2023 Jul 21;18(7):1594-1610. doi: 10.1021/acschembio.3c00212. Epub 2023 Jul 1.
2
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy.光笼型组蛋白去乙酰化酶抑制剂作为靶向癌症治疗中的前药
Pharmaceuticals (Basel). 2023 Feb 25;16(3):356. doi: 10.3390/ph16030356.
3
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
组蛋白去乙酰化酶抑制作用的药物发现:锌结合基团的过去、现在与未来
Pharmaceuticals (Basel). 2025 Apr 16;18(4):577. doi: 10.3390/ph18040577.
4
Origami with small molecules: exploiting the C-F bond as a conformational tool.小分子折纸术:将碳氟键用作构象工具
Beilstein J Org Chem. 2025 Apr 2;21:680-716. doi: 10.3762/bjoc.21.54. eCollection 2025.
5
Mechanism-Based Inhibition of Histone Deacetylase 6 by a Selenocyanate Is Subject to Redox Modulation.硒氰酸盐对组蛋白去乙酰化酶6的基于机制的抑制作用受氧化还原调节。
J Am Chem Soc. 2025 Feb 26;147(8):6373-6377. doi: 10.1021/jacs.5c00157. Epub 2025 Feb 17.
6
Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties.探索组蛋白去乙酰化酶(HDAC)抑制剂中的替代锌结合基团发现,一种具有化学增敏特性的基于乙基肼的强效HDAC抑制剂。
J Med Chem. 2025 Feb 27;68(4):4426-4452. doi: 10.1021/acs.jmedchem.4c02373. Epub 2025 Feb 13.
7
Mechanism-Based Inhibition of Histone Deacetylase 6 by a Selenocyanate is Subject to Redox Modulation.硒氰酸盐对组蛋白去乙酰化酶6的基于机制的抑制作用受氧化还原调节。
bioRxiv. 2025 Jan 4:2025.01.04.631333. doi: 10.1101/2025.01.04.631333.
8
Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.二氟甲基-1,3,4-噁二唑类 HDAC6 抑制剂的作用机制和结构见解。
Int J Mol Sci. 2024 May 28;25(11):5885. doi: 10.3390/ijms25115885.
9
Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8.快速测定人组蛋白去乙酰化酶 8 的缓慢结合抑制剂和失活剂的动力学常数。
Int J Mol Sci. 2024 May 21;25(11):5593. doi: 10.3390/ijms25115593.
10
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.催化和抑制 IIb 类组蛋白去乙酰化酶中的化学多功能性。
Acc Chem Res. 2024 Apr 16;57(8):1135-1148. doi: 10.1021/acs.accounts.3c00801. Epub 2024 Mar 26.
羟肟酸和二氟甲基恶二唑类组蛋白去乙酰化酶 6 抑制剂的体外和细胞选择性。
Int J Mol Sci. 2023 Mar 1;24(5):4720. doi: 10.3390/ijms24054720.
4
Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.二氟甲基-1,3,4-噁二唑类化合物是组蛋白去乙酰化酶 6 的缓慢结合底物类似物抑制剂,具有前所未有的同型选择性。
J Biol Chem. 2023 Jan;299(1):102800. doi: 10.1016/j.jbc.2022.102800. Epub 2022 Dec 15.
5
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.氟代肽基组蛋白去乙酰化酶(HDAC)抑制剂的开发用于治疗耐药性急性白血病。
J Med Chem. 2022 Nov 24;65(22):15457-15472. doi: 10.1021/acs.jmedchem.2c01418. Epub 2022 Nov 9.
6
AMX - the highly automated macromolecular crystallography (17-ID-1) beamline at the NSLS-II.NSLS-II 上的高度自动化大分子晶体学(17-ID-1)光束线 AMX。
J Synchrotron Radiat. 2022 Nov 1;29(Pt 6):1480-1494. doi: 10.1107/S1600577522009377. Epub 2022 Oct 21.
7
Development of the first non-hydroxamate selective HDAC6 degraders.开发首个非羟肟酸类选择性 HDAC6 降解剂。
Chem Commun (Camb). 2022 Oct 4;58(79):11087-11090. doi: 10.1039/d2cc03712b.
8
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.首个基于酰腙的 HDAC6 选择性抑制剂,通过抑制 NLRP3 炎性小体激活发挥强效口服抗炎活性。
J Med Chem. 2022 Sep 22;65(18):12140-12162. doi: 10.1021/acs.jmedchem.2c00853. Epub 2022 Sep 8.
9
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.靶向特发性肺纤维化中的组蛋白去乙酰化酶:未来的治疗选择。
Cells. 2022 May 12;11(10):1626. doi: 10.3390/cells11101626.
10
Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.平衡组蛋白去乙酰化酶(HDAC)抑制和类药性:I 类选择性 HDAC 抑制剂的生物学和物理化学评价。
ChemMedChem. 2022 May 4;17(9):e202100755. doi: 10.1002/cmdc.202100755. Epub 2022 Feb 18.